Overview of Dexatil

Property	Description
Active ingredient	Cefuroxime (as axetil or sodium salt)
Form	Tablets, Oral Suspension, Powder for Injection
Pharmacological class	Cephalosporin Antibiotic (Second Generation)
Common use	Systemic treatment of bacterial infections
Origin	Semisynthetic

Defining Dexatil: The Second-Generation Cephalosporin

Dexatil is a pharmaceutical preparation whose active component is the semisynthetic chemical substance, Cefuroxime. This compound is classified as a cephalosporin antibiotic and belongs specifically to the second generation of these agents. This classification reflects the drug's enhanced stability against certain bacterial enzymes, which is a key differentiator in its pharmacological profile. It functions as a bactericidal agent, meaning it actively kills susceptible bacteria by interfering with their structural integrity. Cefuroxime is categorized as an essential medicine, underscoring its long-standing, clinically recognized importance in global public health.

The Purpose of Dexatil as an Antibacterial Drug

The general purpose of this medicine is achieved by targeting the fundamental cause of bacterial illnesses. Cefuroxime is a beta-lactam agent that specifically inhibits the final steps in bacterial cell wall synthesis. This highly specific action leads to the structural collapse and death of the organism, providing a robust method for clearing infection. The compound has demonstrated reliable efficacy against susceptible pathogens across various infection types, such as those commonly affecting the respiratory tract or skin, resolving the underlying bacterial presence.

Available Forms and Composition

Dexatil is manufactured as a single-ingredient product available for both oral administration and parenteral administration (injection). For oral use, the compound is formulated as the prodrug Cefuroxime axetil (in film-coated tablets and oral suspension), which is more efficiently absorbed in the digestive tract before converting to the active drug. For intravenous or intramuscular use, the preparation contains Cefuroxime sodium. These distinct compositions ensure that the drug can be effectively delivered into the body via the most appropriate route of administration depending on the clinical context.

Regulatory References

Cefuroxime - Electronic Essential Medicines List

What side effects are possible with Dexatil?

Possible Side Effects and Safety Information

The official safety information for Dexatil, as documented by government regulatory agencies, summarizes potential side effects and necessary usage restrictions. This information is classified by how often the effects occurred in clinical studies and which body system they affect.

Frequency-Classified Adverse Reactions

Side effects are categorized based on their rate of occurrence, ranging from very common (occurring in 1 in 10 or more people) to rare (occurring in fewer than 1 in 1,000 people). These effects are organized by the System-Organ Class (SOC) to provide a clear overview of the body systems affected, such as the nervous system, gastrointestinal tract, or skin.

Classification	Example Systems Involved
Very Common	Nervous System, Gastrointestinal Disorders
Common	Skin and Subcutaneous Tissue Disorders
Uncommon/Rare	Hepatic Disorders, Cardiac Disorders

Clinically Significant and Serious Adverse Reactions

The regulatory profile highlights specific events considered serious or clinically significant, which may necessitate medical intervention or specialized monitoring. These reactions are identified separately to ensure they receive immediate attention.

Restrictions and Limitations on Use

Safety documents define formal contraindications—conditions, diseases, or co-administered medicines that officially prohibit the use of Dexatil due to documented unacceptable risk. Furthermore, specific warnings outline circumstances, such as pre-existing hepatic or renal impairment, where the medicine must be used with heightened caution or requires formal safety monitoring (e.g., periodic laboratory testing) as specified in the regulatory label. These restrictions formally define the patient populations and conditions for which the risk profile is deemed too high.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Dexatil (Cefuroxime) overdose is defined by the potential for severe central nervous system effects. The most serious documented manifestations of taking excessive amounts include convulsions, seizures, and encephalopathy. These neurological symptoms indicate severe toxicity.

When to Seek Immediate Medical Help

Individuals must seek immediate medical attention for a suspected overdose. The regulatory guidance instructs contacting emergency services immediately (e.g., 911 or equivalent) if the individual exhibits severe signs such as collapse, a seizure, trouble breathing, or inability to be awakened. Furthermore, contact with a Poison control helpline is advised.

Management and Population Risk

In cases of severe overdose, the compound is known to be effectively removed from the body using official procedural measures, specifically haemodialysis and peritoneal dialysis. No specific antidote is listed in the regulatory documents reviewed for Cefuroxime overdose; therefore, management focuses on supportive care and drug elimination. A specific regulatory note highlights that overdose symptoms can occur in patients with markedly impaired renal function if the required dosage adjustments for slower drug clearance are not implemented.

Therapeutic Uses of Dexatil

What Dexatil Treats: Main Uses and Benefits

Dexatil, which contains cefuroxime axetil, is commonly used to help with conditions presenting with systemic or localized discomfort across multiple body systems. The medicine is applied to address the bacterial cause of these conditions and is relevant in contexts involving heightened systemic burden. It is commonly used for managing conditions such as pharyngitis, acute bacterial sinusitis, otitis media, pneumonia, uncomplicated UTIs, early Lyme disease, and uncomplicated skin infections.

Therapeutic Benefit

This medication is primarily relevant for easing symptoms in the respiratory tract and other domains. It helps address symptom clusters related to physical discomfort and systemic imbalance, including fever and localized pain. The use contributes to easing the overall symptom load, offering symptomatic relief that may help patients cope more steadily with difficult acute episodes and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Localized Pain and Fever Dexatil helps address acute, localized symptoms like ear pain or sinus pressure, and systemic symptoms like fever, by addressing the underlying bacterial cause.

Regulatory References

DailyMed Cefuroxime Axetil Label

Eligibility and Restrictions for Use

Eligibility for Dexatil (Ceftriaxone-based product)

Dexatil is generally intended for adults and pediatric patients who are 3 months of age and older. However, its use is strictly prohibited in several specific populations and clinical situations, as defined by regulatory documents.

Eligibility Status	Patient Group or Condition
Contraindicated	Known hypersensitivity to ceftriaxone, lidocaine (if used as diluent), or any cephalosporin antibiotic.
Contraindicated	Neonates (aged 28 days or younger) who require, or are expected to require, intravenous calcium-containing solutions. This restriction applies regardless of the administration line.
Contraindicated	Hyperbilirubinemic neonates and preterm neonates (up to 41 weeks corrected gestational age) due to the risk of bilirubin displacement.
Use Not Established	Children younger than 3 months of age for most indications.

For patients with severe renal impairment, especially those with concurrent liver disease, caution is required, and the dosage may need adjustment. The safety profile regarding pregnancy and lactation has not resulted in a formal prohibition or allowance status, but use requires careful consideration of documented risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the formally documented interaction patterns for Dexatil (Cefuroxime axetil) as stated in official government regulatory information.

Documented Pharmacokinetic and Clearance Interactions

Interacting Substance	Official Interaction Outcome	Regulatory Status/Restriction
Probenecid	Significantly increases the systemic exposure, peak concentration left(Cmax
ight), and elimination half-life of Cefuroxime by inhibiting renal tubular secretion.	Coadministration not recommended.
Drugs that reduce gastric acidity (e.g., H2-blockers, PPIs, Antacids)	Results in lower bioavailability of Cefuroxime axetil, counteracting the effect of enhanced postprandial absorption.	Reduced systemic exposure risk.

Pharmacodynamic and Absorption Interactions

Interacting Substance	Official Interaction Outcome	Risk Classification
Combined Oral Contraceptives	May affect gut flora, potentially leading to reduced effectiveness due to lowered estrogen reabsorption.	Reduced Efficacy Risk.
Food	Absorption of Cefuroxime axetil is enhanced when the product is taken after food.	Enhanced Bioavailability Condition.

Laboratory Test Interference

Cefuroxime interferes with glucose testing methods. The medicine causes false-positive results with copper reduction tests for urinary glucose (e.g., Benedict's) and false-negative results in the ferricyanide test for blood/plasma glucose.

Mechanism of Action

How Dexatil Works

Irreversible Inhibition of Bacterial Cell Wall Synthesis

The primary mechanism of Dexatil involves the molecule binding covalently to and permanently inactivating Penicillin-Binding Proteins (PBPs), which are essential bacterial enzymes. This interaction critically blocks the final steps of peptidoglycan cross-linking, which is necessary for the structural integrity of the bacterial cell wall, leading to a critical structural failure within the bacterial cell.

Lysis and Systemic Clearance of Viable Bacteria

By compromising the cell wall structure, the drug initiates a fatal cascade where the high internal osmotic pressure of the bacteria cannot be contained. This leads directly to the osmotic lysis (rupture and dissolution) of the bacterial cell. This specific, bactericidal action destroys the targeted bacterial cells, resulting in the elimination of the viable bacterial population in the system.

️ Constraints and Mechanism Limitations

The function of this bactericidal mechanism is inherently limited by bacterial defense strategies, notably the production of beta-lactamase enzymes that chemically degrade the drug before it can reach the PBPs. Furthermore, structural changes in the PBP targets themselves can reduce the drug's binding affinity, diminishing the initial molecular action and inhibiting the subsequent destructive cascade.

Dosage and Administration Information

Dexatil is administered using two distinct forms: oral (Cefuroxime axetil) and parenteral (Cefuroxime sodium), with the route and dose specified for different clinical indications.

Official Dosing and Administration

Administration Route	Standard Adult Dosing	Typical Frequency & Duration
Oral (Tablets/Suspension)	250 mg or 500 mg	Every 12 hours. Course usually lasts 7 to 10 days, but up to 20 days for early Lyme disease.
Parenteral (IV/IM Injection)	750 mg to 1.5 g	Every 8 hours (three times daily). Increased frequency (every 6 hours) is used for severe infections.

Key Instructions for Proper Use

1. Intake Conditions: The oral suspension must be administered with food to maximize absorption. Tablets may be taken with or without food, but should never be crushed or chewed; they must be swallowed whole.

2. Parenteral Preparation: The powder for injection must be reconstituted with the appropriate sterile diluent prior to administration. Intravenous bolus doses are to be given over 3 to 5 minutes, or via infusion over 30 to 60 minutes.

3. Population Adjustments: Dose frequency requires adjustment in patients with impaired renal function (creatinine clearance <30 mL/min) to compensate for slower drug excretion, potentially extending the interval to every 24 or 48 hours. A supplementary 750 mg dose is typically given at the end of each hemodialysis session. The tablet and suspension formulations are not substitutable on a milligram-per-milligram basis.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Compound A Research

Studies have evaluated the use of Compound A in individuals with long-term joint discomfort and reduced movement. Evaluations examined changes in joint mobility and chronic pain measures. Research explored the duration and extent of changes in inflammation markers.

The patient populations evaluated in the research primarily included individuals with mild to moderate symptoms. The study findings indicated that after 12 weeks of use, measures of discomfort changed. Preclinical research explored the compound's effect on inflammatory markers.

Phase 3 Trial: This Phase 3 trial included over 500 participants. The primary outcome measure was a change in the established pain scale score.

Combination Therapy (Compound A + Compound B) Studies

Research has also explored the effects of Compound A when administered alongside Compound B. These studies aimed to examine whether the two compounds, when taken together, were associated with different measures of discomfort and physical function than either compound alone.

Clinical Efficacy Evaluations

Causal Link: One study comparing the combined treatment to placebo reported different outcomes between the groups. This research explored whether the combination was associated with changes in a specific biomarker.
Function and Quality of Life: Evaluations explored changes in quality of life measures and physical function in the groups receiving the combination compared to those receiving single agents.

Important Note on Interpretation

This summary describes the findings of specific research evaluations. The information provided is descriptive of study outcomes and does not constitute medical advice or a recommendation for use.

Frequently Asked Questions (FAQ)

Common questions about Dexatil (FAQ)

Q: Is Dexatil the same type of medicine as [similar drug name]? What's the difference?

Dexatil is officially classified as a second-generation cephalosporin antibiotic. This classification places it in a specific group of antibacterial drugs. The official product description indicates that this class of medicine has an enhanced ability to resist certain bacterial defense enzymes compared to earlier generation agents.

Q: How quickly should someone expect Dexatil to start working?

Regulatory documents indicate that the active drug is quickly absorbed and reaches its highest level in the bloodstream about an hour after an oral dose. Official information indicates that symptomatic improvement in clinical trials was generally observed within 48 hours. However, individual patient response can vary.

Q: Is it true that Dexatil is only for short-term use?

Yes, Dexatil is generally intended for the short-term treatment of specific bacterial infections. The regulatory prescribing information defines typical course durations, such as 7 to 10 days for many infections. Some conditions, like early Lyme disease, may require a longer course of up to 20 days.

Q: What happens if a dose of Dexatil is missed?

Regulatory patient instructions describe that if a dose is missed, taking it as soon as it is remembered may be an option. However, if it is nearly time for the next scheduled dose, the missed dose is usually skipped, and the regular schedule is resumed. It is not recommended to take a double dose to make up for a missed one.

Q: What kind of warnings are included on the Dexatil prescription label?

The official label includes several significant warnings and precautions. These address the potential for serious allergic reactions (anaphylaxis) and the risk of a serious intestinal complication known as Clostridioides difficile-associated diarrhea (CDAD). Warnings also cover possible issues like microbial overgrowth and interference with certain laboratory tests.

Q: What is the official risk level for Dexatil and breastfeeding?

Official safety data indicates that the drug's active component, Cefuroxime, is excreted in human milk. Regulatory information notes the decision to discontinue nursing is often considered during the course of treatment with this medicine.

Q: What is the general timeline for achieving the full effect of Dexatil?

While the drug becomes available in the bloodstream quickly, the full therapeutic effect against the infection may not be reached until the entire prescribed course is completed. Patients are instructed to follow the full prescribed schedule, as completion of the course is necessary to effectively address the infection.

Q: Why is regular monitoring mentioned in the official Dexatil documents?

Monitoring is specified for certain patient groups, particularly those with severe kidney or liver problems. Monitoring is specified to ensure changes in certain laboratory values or organ function, particularly in high-risk patients, are consistently assessed according to official protocols.

Q: Does Dexatil affect the ability to drive or operate machinery?

Official safety profiles list potential nervous system side effects such as headache, dizziness, and somnolence (sleepiness). The potential occurrence of these effects may be associated with an impaired ability to safely drive or operate complex machinery.

Q: What is the general advice about stopping Dexatil use?

Official patient guidance consistently emphasizes the importance of completing the full course of the medicine as prescribed, even when symptoms show early signs of improvement. Stopping the antibiotic course too soon can increase the likelihood of the infection returning and may contribute to the development of drug-resistant bacteria.

Q: What type of healthcare provider can prescribe Dexatil?

Dexatil is classified as a prescription-only medicine. This means that it is only available when prescribed by a licensed healthcare professional who is legally authorized to issue prescriptions for medications.

Q: What is the general duration of treatment described for Dexatil?

The length of treatment is determined by the specific type of bacterial infection being addressed. However, official information describes typical courses ranging from 7 to 10 days. Longer courses, such as up to 20 days, are reserved for specific uses like early Lyme disease.

Q: Does Dexatil have a common effect on sleep patterns?

Official safety data reports somnolence, which is a term for sleepiness, as one of the documented adverse reactions. Other reported effects affecting the nervous system include headache and dizziness.

Q: What are the most commonly reported side effects of Dexatil?

Based on clinical trial data published in official safety documents, the most common adverse reactions reported are diarrhea, nausea/vomiting, and vaginitis (a yeast infection). The safety profile also highlights the Jarisch-Herxheimer reaction, which can occur during treatment for certain infections like Lyme disease.

Q: Are there any known food restrictions while using Dexatil?

Official warnings note that the drug's absorption can be reduced by medicines that decrease stomach acid, such as antacids. While the oral suspension must be taken with food for better absorption, there are no specific restrictions on consuming particular types of food during treatment.

Q: Is there a known risk of dependence with Dexatil?

Dexatil is classified as an antibiotic and is not listed as a controlled substance by major regulatory bodies. Furthermore, there is no mention of any risk of physical dependence in the official prescribing information for the drug.

Q: How long does Dexatil typically stay in the body after the last use?

The drug's active substance is eliminated relatively quickly. In adults with typical kidney function, the official pharmacokinetic data indicates an elimination half-life of approximately 1.2 to 1.5 hours. The half-life describes the time it takes for half of the drug to be removed from the body.

Q: What are the results of the key clinical trials for Dexatil?

The clinical trials served as the foundation for the drug's approval for use against a range of bacterial illnesses. Official study summaries confirmed the drug’s effectiveness for approved uses, which include infections of the respiratory tract, ear, skin, and urinary tract.

Q: Are there different versions or brands of Dexatil available?

Yes, official drug listings indicate that the medicine containing the active ingredient Cefuroxime axetil is marketed under its original brand name, Dexatil. It is also commonly available as a generic version.

Q: What is the risk of having a serious interaction with Dexatil?

The official Warnings and Precautions section outlines serious risks. These include the potential for rare, but life-threatening, hypersensitivity reactions (anaphylaxis). The risk of serious infections, such as Clostridioides difficile-associated diarrhea, is also noted in the prescribing information.

Q: Is Dexatil commonly associated with changes in mood or anxiety?

Specific changes to mood or anxiety are generally not listed as common side effects in the official safety profile. However, adverse reactions affecting the nervous system that have been reported include headache and dizziness.

Q: Can Dexatil be used for prevention of a condition?

The medicine is primarily approved for the treatment of established bacterial infections. However, official regulatory documents also reference the use of Cefuroxime for prophylaxis (prevention) in connection with certain types of surgical procedures.

Q: Are there specific patient groups where Dexatil requires caution?

Official warnings advise caution for several patient groups. These include people with a history of colitis, those with gastrointestinal malabsorption, and patients with existing kidney or liver impairment. Caution is also noted for patients taking certain diuretics.

Q: Is it normal to feel a change in energy levels when starting Dexatil?

Official safety data does not specifically detail changes to energy levels as a common side effect. However, the documentation notes general adverse reactions such as somnolence (sleepiness) and chills.

Q: Why is there a Black Box Warning (or similar serious warning) mentioned for Dexatil?

According to the official prescribing information from the FDA, Dexatil (Cefuroxime axetil) does not contain a Boxed Warning. Nonetheless, the label does contain serious warnings concerning the potential for anaphylactic reactions and Clostridioides difficile-associated diarrhea.

How should Dexatil be stored and disposed of?

Official Storage and Disposal Instructions

Storage and handling requirements for Dexatil (Cefuroxime) are defined by the medicine's specific formulation, ensuring stability and potency.

Product Form	Storage Requirement	Shelf-Life After Preparation
Tablets/Unreconstituted Powder	Store below 30 C, protect from moisture, and keep in the original container.	Remains stable until the labeled expiry date.
Reconstituted Oral Suspension	Refrigerate at 2 C to 8 C immediately after mixing.	Must be discarded after 10 days.

All forms of Dexatil must be stored securely and kept out of the reach and sight of children. To dispose of unused or expired medicine, regulatory guidelines mandate that the product or any related waste material be discarded in accordance with local regulations.

Dexatil